Celcuity LLC
NASDAQ: CELC · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-12
Celcuity LLC (CELC) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-1.98M | $-2.89M | $-4.95M | $-6.08M | $-6.00M | $-7.15M | $-20.31M | $-36.01M | $-53.81M | $-83.47M | $-153.28M |
| Capital expenditures | $78982.00 | $40903.00 | $239848.00 | $629608.00 | $380201.00 | $89371.00 | $81898.00 | $158768.00 | $97644.00 | $249878.00 | $249000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $56507.00 | $187306.00 | $874386.00 | $1.17M | $1.04M | $1.76M | $2.61M | $4.64M | $4.90M | $6.99M | $21.38M |
| Free cash flow | $-2.06M | $-2.93M | $-5.19M | $-6.71M | $-6.38M | $-7.24M | $-20.39M | $-36.17M | $-53.91M | $-83.72M | $-153.53M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $-3.22M | $13.25M | $2.79M | $-7.10M | $72.65M | $-59.71M | — | — | — |
Frequently asked questions
How profitable is CELC?
In its most recent fiscal year, CELC ran a gross margin of -108.44%, an operating margin of -111,812.99%, and a net margin of -114,962.34%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does CELC generate?
CELC produced $-153.53M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is CELC's balance sheet healthy?
CELC holds $165.70M in cash and equivalents against $321.85M in long-term debt, on $100.56M of shareholder equity. That debt is best read against the cash flow the business throws off each year.